Skip to content

Study · Observational study · n = 16,402 · 2026

4 results

Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

Wu JY, Lee KW, Kao CL, Hung KC, Yu T, Lin YM

Journal of the American Heart Association17 Jul 2026

PMID42466510 (opens in a new tab)PMCIDPMC13477337 (opens in a new tab)DOI10.1161/jaha.125.047018 (opens in a new tab)PepBankPUB-42466510
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was associated with a lower 1-year risk of MACE than GLP-1 receptor agonists.

    In plain wordsIn adults with type 2 diabetes and heart or vessel disease, tirzepatide was linked to fewer serious heart events than other GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    Decrease1-year major adverse cardiovascular events (MACE)
    Study

    n = 16,402

    Comparator
    GLP-1 receptor agonists
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.75 ratio
    MACE

    Source sentences

    Summary
    Tirzepatide was associated with a lower risk of major adverse cardiovascular events (hazard ratio [HR], 0.75 [95% CI, 0.63-0.91])
    2 context sentences
    Summary · context
    A total of 16 402 patients with type 2 diabetes and atherosclerotic cardiovascular disease initiating tirzepatide or GLP-1 receptor agonists between January 1, 2022, and March 31, 2025 were matched 1:1.
    Summary · context
    The primary outcome was 1-year major adverse cardiovascular events; secondary outcomes included all-cause mortality, acute myocardial infarction, major adverse limb events, and tissue plasminogen activator use.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was associated with lower all-cause mortality than GLP-1 receptor agonists.

    In plain wordsIn adults with type 2 diabetes and heart or vessel disease, tirzepatide was linked to fewer deaths than other GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality
    Study

    n = 16,402

    Comparator
    GLP-1 receptor agonists
    Analysis
    Secondary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.69 ratio
    all-cause mortality

    Source sentences

    Summary
    all-cause mortality (HR, 0.69 [95% CI, 0.53-0.90])
    2 context sentences
    Summary · context
    A total of 16 402 patients with type 2 diabetes and atherosclerotic cardiovascular disease initiating tirzepatide or GLP-1 receptor agonists between January 1, 2022, and March 31, 2025 were matched 1:1.
    Summary · context
    The primary outcome was 1-year major adverse cardiovascular events; secondary outcomes included all-cause mortality, acute myocardial infarction, major adverse limb events, and tissue plasminogen activator use.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was associated with a lower risk of major adverse limb events than GLP-1 receptor agonists.

    In plain wordsIn adults with type 2 diabetes and heart or vessel disease, tirzepatide was linked to fewer serious leg and foot events than other GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse limb events
    Study

    n = 16,402

    Comparator
    GLP-1 receptor agonists
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.59 ratio
    major adverse limb events

    Source sentences

    Summary
    major adverse limb events (HR, 0.59 [95% CI, 0.39-0.88])
    2 context sentences
    Summary · context
    A total of 16 402 patients with type 2 diabetes and atherosclerotic cardiovascular disease initiating tirzepatide or GLP-1 receptor agonists between January 1, 2022, and March 31, 2025 were matched 1:1.
    Summary · context
    The primary outcome was 1-year major adverse cardiovascular events; secondary outcomes included all-cause mortality, acute myocardial infarction, major adverse limb events, and tissue plasminogen activator use.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was associated with a lower risk of acute myocardial infarction than GLP-1 receptor agonists.

    In plain wordsIn adults with type 2 diabetes and heart or vessel disease, tirzepatide was linked to fewer heart attacks than other GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAcute myocardial infarction
    Study

    n = 16,402

    Comparator
    GLP-1 receptor agonists
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.7 ratio
    acute myocardial infarction

    Source sentences

    Summary
    acute myocardial infarction (HR, 0.70 [95% CI, 0.53-0.93]), compared with GLP-1 receptor agonists.
    2 context sentences
    Summary · context
    A total of 16 402 patients with type 2 diabetes and atherosclerotic cardiovascular disease initiating tirzepatide or GLP-1 receptor agonists between January 1, 2022, and March 31, 2025 were matched 1:1.
    Summary · context
    The primary outcome was 1-year major adverse cardiovascular events; secondary outcomes included all-cause mortality, acute myocardial infarction, major adverse limb events, and tissue plasminogen activator use.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.